RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
Ying-Jung HuangHsi-Che LiuTang-Her JaingKang-Hsi WuShih-Chung WangHsiu-Ju YenChih-Cheng HsiaoShih-Hsiang ChenPei-Chin LinTing-Chi YehJiunn-Ming SheenYu-Chieh ChenTe-Kau ChangFang-Liang HuangYu-Hua ChaoJen-Yin HouChao-Ping YangTung-Huei LinLee-Yung ShihPublished in: Pediatric blood & cancer (2021)
Our results showed that RAS pathway mutation is an added-value biomarker in pediatric IKZF1-deleted Ph (-) ALL patients.